Deciphera Pharmaceuticals (DCPH) Prices 3.18M Share Common Offering at $55/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/19/2026
- Wall St ends lower for the day and week as chip selloff broadens
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Medifast launches Trilivy, replacing its Optavia brand
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Adobe has received a takeover approach by a Big Tech company - Betaville
Deciphera Pharmaceuticals (DCPH) Announces FDA Acceptance of NDA and Priority Review for Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors
February 12, 2020 4:41 PM ESTDeciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its New Drug Application (NDA) seeking approval for ripretinib, the Companys investigational broad-spectrum KIT and PDGFR inhibitor, for the treatment of patients with... More
Deciphera Pharmaceuticals (DCPH) to Offer $250M in Stock
February 12, 2020 4:15 PM ESTDeciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) announced the commencement of a registered underwritten public offering of $250.0 million in shares of its common stock. In addition, Deciphera intends to grant the underwriters a 30-day option to purchase up to $37.5 million in shares of its... More
